From this basis emerged the clinical confidence that diagnostic truth lived somewhere at the far end of a resolution curve. Butterfly Network may be challenging that premise from the ground up.

There are potential risks in the MR environment, not only for the patient but also for the accompanying healthcare professionals. The MRI screening process, when performed properly, ensures ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for ...

With this approval, AMBELVIST becomes the lowest-dose mGBCA in the U.S. AMBELVIST has a recommended dose of 0.01 mmol/kg actual body weight (which delivers 0.04 mmol Gd/kg body weight), representing ...